Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

Medexus Pharmaceuticals

Hey y’all, Lucy Copperpot back for more analysis of Equity.Guru companies – this one is no longer on the client list, but I asked for permission to dig in…
We have some 29 companies on our watchlist, all in a variety of sectors, that we’re covering at any one time. Some are clients, some not, some are on…
When you come to a stock pick website like this and see a random story that ;predicts a company will have great revenue growth going forward, hey, I get…
Even though the COVID-19 pandemic posed challenges for healthcare and life sciences companies, Canada’s pharmaceutical industry continued to thrive, thanks to the government’s investments  in pharma which buttressed the…
Medexus Pharmaceuticals (MDP.TO), a specialty pharma company, today announced preliminary revenue estimates for Q4 and the full fiscal year ended March 31st 2023 as well as a business update….
Medexus Pharmaceuticals (MDP.TO), a leading specialty pharma company, today announced that it has secured the Canadian rights to commercialize terbinafine hydrochloride nail lacquer supplied by Polichem, an Almirall group…
Specialty pharma company, Medexus Pharmaceuticals (MDP.TO) released fiscal Q3 2023 (quarter ended December 31st 2022) operating and financial results. The company has announced another record quarter with revenue of…
Medexus Pharmaceuticals (MDP.TO) today announced that it has reached an agreement with the provincial government of Quebec for government sponsored coverage of Cuvposa. The glycopyrrolate oral solution will be…
*originally published 01-16-23 Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing…
Specialty pharma company Medexus Pharmaceuticals (MDP.TO) announced today that it plans to host a conference call at 8:00 am EST on Wednesday November 9th 2022. The call will discuss…